– USA, MA – Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company, today announced the appointment of Bill Meury to its Board of Directors as president and CEO, effective January 3, 2023, to succeed Dr. Steve Paul who will transition to President of research and development and CSO and continue to serve as a Board member
The current lead independent director, Christopher Coughlin will assume the role of chairman of the board.
“Bill’s appointment as president and CEO is the result of a thoughtful succession plan initiated by Steve’s desire to follow his passion, the science, and focus on the continued growth of Karuna’s research and development efforts. As we considered the natural evolution of the Company, Bill’s leadership and expertise in launching and commercializing medicines for psychiatric and neurological conditions was a seamless fit for Karuna, aligning with our strategy for late-stage clinical development and commercialization,” said the lead independent director, Chris Coughlin. “As we look to the future with Bill as CEO and Steve continuing to oversee our research and development efforts, Karuna is very well positioned for continued success in the coming years.”
About Bill Meury
Most recently, Bill Meury served as a partner at Hildred Capital Management, a private equity firm focusing on the healthcare industry. Previously, he was EVP and CCO at Allergan, where he had responsibility for over 50 products with $16 billion in revenue and over $3 billion in sales and marketing investment. He led multiple global divisions in this role, including marketing, sales, business analytics, marketing operations, managed care, pricing, and customer service. Before this role, he served as Allergan’s president, of branded pharma, and EVP, of commercial, North American brands. He also served as EVP of sales and marketing, at Forest before its acquisition by Allergan.
Mr. Meury serves on the board of directors of Syndax Pharmaceuticals and The Jed Foundation. He received a B.S. in economics from the University of Maryland.
“Karuna, with a completely novel pharmacological platform, has the potential to transform the way we think about, and treat, complex psychiatric and neurological conditions,” said Bill Meury. “I have been impressed and inspired by what has been accomplished to date, and I am extremely optimistic about the road ahead as the Company approaches key milestones. I look forward to working alongside Steve, and the incredibly talented Karuna team, as we work toward the same goals – bringing innovative treatment options to those living with serious mental illness and building the capabilities to be a leading neuroscience company in biopharma.”
About Karuna Therapeutics
Karuna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions. At Karuna, we understand there is a need for differentiated and more effective treatments that can help patients navigate the challenges presented by severe mental illness. Utilizing our extensive knowledge of neuroscience, we are harnessing the untapped potential of the brain in pursuit of novel pathways to develop medicines that make meaningful differences in people’s lives.
For more information: https://karunatx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
